153 related articles for article (PubMed ID: 23312237)
1. A review of oral toxicity associated with mTOR inhibitor therapy in cancer patients.
Martins F; de Oliveira MA; Wang Q; Sonis S; Gallottini M; George S; Treister N
Oral Oncol; 2013 Apr; 49(4):293-8. PubMed ID: 23312237
[TBL] [Abstract][Full Text] [Related]
2. Mammalian target of rapamycin inhibitor-associated stomatitis.
Boers-Doets CB; Raber-Durlacher JE; Treister NS; Epstein JB; Arends AB; Wiersma DR; Lalla RV; Logan RM; van Erp NP; Gelderblom H
Future Oncol; 2013 Dec; 9(12):1883-92. PubMed ID: 24295418
[TBL] [Abstract][Full Text] [Related]
3. Clinical presentation and management of mTOR inhibitor-associated stomatitis.
de Oliveira MA; Martins E Martins F; Wang Q; Sonis S; Demetri G; George S; Butrynski J; Treister NS
Oral Oncol; 2011 Oct; 47(10):998-1003. PubMed ID: 21890398
[TBL] [Abstract][Full Text] [Related]
4. Oral stomatitis and mTOR inhibitors: A review of current evidence in 20,915 patients.
Lo Muzio L; Arena C; Troiano G; Villa A
Oral Dis; 2018 Mar; 24(1-2):144-171. PubMed ID: 29480626
[TBL] [Abstract][Full Text] [Related]
5. Incidence and risk of high-grade stomatitis with mTOR inhibitors in cancer patients.
Shameem R; Lacouture M; Wu S
Cancer Invest; 2015 Mar; 33(3):70-7. PubMed ID: 25635371
[TBL] [Abstract][Full Text] [Related]
6. Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients.
Sonis S; Treister N; Chawla S; Demetri G; Haluska F
Cancer; 2010 Jan; 116(1):210-5. PubMed ID: 19862817
[TBL] [Abstract][Full Text] [Related]
7. Managing stomatitis in patients treated with Mammalian target of rapamycin inhibitors.
Pilotte AP; Hohos MB; Polson KM; Huftalen TM; Treister N
Clin J Oncol Nurs; 2011 Oct; 15(5):E83-9. PubMed ID: 21951751
[TBL] [Abstract][Full Text] [Related]
8. [Toxicity management for mTOR inhibitors].
Mukohara T
Nihon Rinsho; 2015 Feb; 73 Suppl 2():272-6. PubMed ID: 25831766
[No Abstract] [Full Text] [Related]
9. Cutaneous and mucosal aphthosis during temsirolimus therapy for advanced renal cell carcinoma: review of cutaneous and mucosal side effects of mTOR inhibitors.
De Masson A; Fouchard N; Méry-Bossard L; Dauendorffer JN
Dermatology; 2011; 223(1):4-8. PubMed ID: 21846963
[TBL] [Abstract][Full Text] [Related]
10. Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors.
Quek R; Wang Q; Morgan JA; Shapiro GI; Butrynski JE; Ramaiya N; Huftalen T; Jederlinic N; Manola J; Wagner AJ; Demetri GD; George S
Clin Cancer Res; 2011 Feb; 17(4):871-9. PubMed ID: 21177764
[TBL] [Abstract][Full Text] [Related]
11. Strategies for the management of adverse events associated with mTOR inhibitors.
Kaplan B; Qazi Y; Wellen JR
Transplant Rev (Orlando); 2014 Jul; 28(3):126-33. PubMed ID: 24685370
[TBL] [Abstract][Full Text] [Related]
12. Ridaforolimus: a promising drug in the treatment of soft-tissue sarcoma and other malignancies.
Dancey JE; Monzon J
Future Oncol; 2011 Jul; 7(7):827-39. PubMed ID: 21732754
[TBL] [Abstract][Full Text] [Related]
13. Stomatitis associated with mammalian target of rapamycin inhibition: A review of pathogenesis, prevention, treatment, and clinical implications for oral practice in metastatic breast cancer.
Chambers MS; Rugo HS; Litton JK; Meiller TF
J Am Dent Assoc; 2018 Apr; 149(4):291-298. PubMed ID: 29439772
[TBL] [Abstract][Full Text] [Related]
14. [Use of mTOR-inhibitors in solid tumors].
Seidel C; Grünwald V
Med Monatsschr Pharm; 2011 Apr; 34(4):116-26; quiz 127-8. PubMed ID: 21528529
[TBL] [Abstract][Full Text] [Related]
15. Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors.
Gandhi L; Bahleda R; Tolaney SM; Kwak EL; Cleary JM; Pandya SS; Hollebecque A; Abbas R; Ananthakrishnan R; Berkenblit A; Krygowski M; Liang Y; Turnbull KW; Shapiro GI; Soria JC
J Clin Oncol; 2014 Jan; 32(2):68-75. PubMed ID: 24323026
[TBL] [Abstract][Full Text] [Related]
16. Tolerability, safety and pharmacokinetics of ridaforolimus in combination with bicalutamide in patients with asymptomatic, metastatic castration-resistant prostate cancer (CRPC).
Meulenbeld HJ; de Bono JS; Tagawa ST; Whang YE; Li X; Heath KH; Zandvliet AS; Ebbinghaus SW; Hudes GR; de Wit R
Cancer Chemother Pharmacol; 2013 Oct; 72(4):909-16. PubMed ID: 23921574
[TBL] [Abstract][Full Text] [Related]
17. Incidence and risk of pulmonary toxicity in patients treated with mTOR inhibitors for malignancy. A meta-analysis of published trials.
Iacovelli R; Palazzo A; Mezi S; Morano F; Naso G; Cortesi E
Acta Oncol; 2012 Sep; 51(7):873-9. PubMed ID: 22909392
[TBL] [Abstract][Full Text] [Related]
18. Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine.
Perotti A; Locatelli A; Sessa C; Hess D; Viganò L; Capri G; Maur M; Cerny T; Cresta S; Rojo F; Albanell J; Marsoni S; Corradino I; Berk L; Rivera VM; Haluska F; Gianni L
J Clin Oncol; 2010 Oct; 28(30):4554-61. PubMed ID: 20855840
[TBL] [Abstract][Full Text] [Related]
19. Everolimus: side effect profile and management of toxicities in breast cancer.
Paplomata E; Zelnak A; O'Regan R
Breast Cancer Res Treat; 2013 Aug; 140(3):453-62. PubMed ID: 23907751
[TBL] [Abstract][Full Text] [Related]
20. Drug-induced pneumonitis in cancer patients treated with mTOR inhibitors: management and insights into possible mechanisms.
Duran I; Goebell PJ; Papazisis K; Ravaud A; Weichhart T; Rodriguez-Portal JA; Budde K
Expert Opin Drug Saf; 2014 Mar; 13(3):361-72. PubMed ID: 24517115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
